Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand and Foot Dermatitis
2019-003088-22Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic hand eczema (AHE) and dermatitis comparing Dupilumab with Placebo (2 arms). Primary endpoint: Investigator Global Assessment (hand and foot) response. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
atopic hand eczema (AHE)dermatitis
Beyond the preview
Go deeper on 2019-003088-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003088-22.